Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

falimarev

A cancer vaccine comprised of a recombinant fowlpox viral vector encoding the carcinoembryonic antigen (CEA), MUC-1, a transmembrane glycoprotein secreted by glandular epithelial tissues, and TRICOM, comprised of three co-stimulatory molecule transgenes (B7-1, ICAM-1 and LFA-3). This agent may enhance CEA and MUC-1 presentation to antigen-presenting cells (APC) and may activate a cytotoxic T-cell response against CEA- and MUC-1-expressing tumor cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	recombinant fowlpox-CEA-MUC-1-TRICOM vaccine rfowlpox-CEA(D609)/MUC1(L93)/TRICOM vaccine
US brand name:	PANVAC-F
Abbreviation:	fCEA-MUC-1-TRI

falimarev

Search NCI's Drug Dictionary